Congressional spending plan: What’s in it for healthcare, and what isn’t
Chief Healthcare Executive December 21, 2024
AI Biotech BenevolentAI Restructures Again, This Time to Return to Its TechBio Roots
MedCity News December 11, 2024
BenevolentAI said it will still develop its internally discovered drugs, but will now seek partners for them earlier in their development. Going forward, BenevolentAI will focus on making its AI technologies available to support the drug R&D efforts of its partners.
Artificial intelligence biotech firm BenevolentAI is reorganizing its operations for the second time in less than two years, and this time it says the changes will take the company back to its original mission of serving biopharma industry partners.
Going forward, London-based BenevolentAI will refocus its efforts on its core technologies for drug discovery and development. The Wednesday announcement offered few financial details, but the company did say the coming changes include plans to take the company private.
BenevolentAI...
Today's Sponsors
Today's Sponsor